EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 6

Sutherlandia (cancer bush) Lessertia frutescens (L.) Goldblatt & J.C.Manning

Also called: Sutherlandia frutescens (L.) W.T.Aiton (synonym), sutherlandia, cancer bush, kankerbos, balloon-pea

Sutherlandia is a southern African shrub used in traditional medicine, generally consumed as a tea; clinical trials used capsules of dried leaf powder or dried plant material. Despite the name "cancer bush", anticancer effects have been seen only in laboratory studies, not in people.

Category
Botanical
Part used
Leaves; tea, or dried leaf powder in capsules
Strongest evidence
C Limited
Native range
Native to southern Africa (POWO: "S. Africa"; WCVP distribution: Botswana, Namibia, Lesotho and South African provinces); introduced in Kenya, Mexico and Australia
Reviewed
2026-10-29

Class 3 Limited studies in people. No review stating a count was found. This entry cites 2 RCTs of Sutherlandia alone: leaf powder versus placebo in 25 healthy adults (2007) and in HIV-positive adults (2015, 107 analyzed). A third cited study was a non-randomized drug-interaction study. [2]

Fact-checked 2026-10-29 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

3 topics studied3 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Sutherlandia (cancer bush) does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Sutherlandia (cancer bush), evidence grade and finding
Topic studiedGradeWhat the evidence shows
Safety and tolerability in healthy adultsCIn a 3-month randomized, placebo-controlled pilot trial of 25 healthy adults, 800 mg/day of leaf powder caused no more adverse events than placebo; users reported improved appetite. [2]
HIV viral load and CD4 count in adults with HIVCIn a 24-week randomized, placebo-controlled trial (107 analyzed), 1,200 mg twice daily did not change viral load or CD4 count, and days of infection-related events were higher with sutherlandia. [3]
CancerDAnticancer and other activities come from laboratory studies; MSK notes that whether sutherlandia could be used for cancer has not been studied in humans. [1]

Main constituents: Pinitol and GABA (gamma-aminobutyric acid) in the leaves [1]; Canavanine, used as a Sutherlandia biomarker [2]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • 400 mg leaf-powder capsules twice daily (800 mg/day) for 3 months (healthy-adult safety trial). [2]
  • 400, 800 or 1,200 mg twice daily for 24 weeks (HIV safety trial). [3]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    3 listed

    Atazanavir; Isoniazid; CYP3A4 and P-glycoprotein substrates

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    See details

    FDA does not approve dietary supplements.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • In the HIV trial, two participants taking sutherlandia with isoniazid preventive therapy developed tuberculosis; the authors flag a possible interaction needing evaluation. [3]
  • Common side effects: diarrhea, dry mouth and dizziness; rarely sweating and vomiting at high doses. [1]
Interactions

Interactions

Sutherlandia (cancer bush)
From the table below 3 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of Sutherlandia (cancer bush)
WithWhat happens
AtazanavirIn 12 healthy men, 12 days of milled sutherlandia lowered atazanavir exposure (AUC ratio 0.801; Cmax ratio 0.783), which may risk subtherapeutic levels. [4]
IsoniazidMSK advises people taking isoniazid to avoid sutherlandia because it may interfere with the drug's effectiveness. [1]
CYP3A4 and P-glycoprotein substrates (including antiretrovirals)Sutherlandia inhibited CYP3A4 and P-glycoprotein in vitro, but in a rat study it induced CYP3A and decreased intracellular nevirapine concentrations; clinical relevance has not been determined. [1]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Regulation

Regulatory status

  • US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; manufacturers and distributors have initial responsibility for their safety. [5]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Pinitol Cyclitol (sugar alcohol) [P1]
  • GABA (gamma-aminobutyric acid) Non-protein amino acid [P1]
  • Canavanine (Sutherlandia biomarker) Non-protein amino acid [P2]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI list (dated July 9, 2026; checked 2026-10-29) has 3 notifications naming sutherlandia (Sutherlandia frutescens, now Lessertia frutescens): NDI 131 (Rpt/NDI 108), submitted 2001-11-27, FDA response dated 2002-02-08; NDI 237 (Rpt/NDI 199), leaf powder, submitted 2003-07-01, response dated 2003-09-11; NDI 573, leaf and stem, submitted 2009-01-27, response dated 2009-04-10. The list gives the date of FDA's response letter but not what it said. [P3]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of sutherlandia (Lessertia frutescens) was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P4]
  • NTP technical reports list checked 2026-10-29: no report on sutherlandia. [P5]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • Atazanavir: In 12 healthy men, milled sutherlandia twice daily for 12 days reduced atazanavir AUC (ratio 0.801) and Cmax (ratio 0.783), with confidence intervals below the no-effect boundary. [P6]
  • Isoniazid: Two participants taking sutherlandia with isoniazid preventive therapy developed tuberculosis in a 24-week HIV trial; a possible interaction needs further evaluation. [P7]
  • CYP3A4 and P-glycoprotein substrates: Inhibited CYP3A4 and P-glycoprotein in vitro; in a rat study, induction of CYP3A decreased intracellular nevirapine concentrations. Clinical relevance not determined. [P1]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination of each dietary-ingredient component (21 CFR 111.75(a)(1)(i)) — Required by the US dietary supplement cGMP rule for any component that is a dietary ingredient, unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P8]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • In healthy adults taking 800 mg/day of leaf powder for 3 months, the biomarker canavanine was undetectable in plasma. [P2]

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. Memorial Sloan Kettering Cancer Center. About Herbs: Sutherlandia frutescens (last updated July 12, 2022), 2022-07-12. mskcc.org
  2. Johnson Q, et al. A randomized, double-blind, placebo-controlled trial of Lessertia frutescens in healthy adults. PLoS Clin Trials 2007;2(4):e16 (PMID 17476314), 2007-04-27. pubmed.ncbi.nlm.nih.gov
  3. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  4. IARC Monographs. List of Classifications, Agents classified by the IARC Monographs, Volumes 1–142 (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
  5. National Toxicology Program (NIEHS). Technical Reports list (checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
  6. Müller AC, et al. Effect of the African Traditional Medicine, Sutherlandia frutescens, on the Bioavailability of the Antiretroviral Protease Inhibitor, Atazanavir. Evid Based Complement Alternat Med 2013:324618 (PMID 24416065), 2013. pubmed.ncbi.nlm.nih.gov
  7. Wilson D, et al. Consumption of Sutherlandia frutescens by HIV-Seropositive South African Adults: An Adaptive Double-Blind Randomized Placebo Controlled Trial. PLoS One 2015;10(7):e0128522 (PMID 26186450), 2015. pubmed.ncbi.nlm.nih.gov
  8. eCFR. 21 CFR 111.75 (Title 21 up to date as of 10/27/2026), 2026-10-27. ecfr.gov
Sources

Sources

  1. Memorial Sloan Kettering Cancer Center. About Herbs: Sutherlandia frutescens (last updated July 12, 2022), 2022-07-12. mskcc.org
  2. Johnson Q, et al. A randomized, double-blind, placebo-controlled trial of Lessertia frutescens in healthy adults. PLoS Clin Trials 2007;2(4):e16 (PMID 17476314), 2007-04-27. pubmed.ncbi.nlm.nih.gov
  3. Wilson D, et al. Consumption of Sutherlandia frutescens by HIV-Seropositive South African Adults: An Adaptive Double-Blind Randomized Placebo Controlled Trial. PLoS One 2015;10(7):e0128522 (PMID 26186450), 2015. pubmed.ncbi.nlm.nih.gov
  4. Müller AC, et al. Effect of the African Traditional Medicine, Sutherlandia frutescens, on the Bioavailability of the Antiretroviral Protease Inhibitor, Atazanavir. Evid Based Complement Alternat Med 2013:324618 (PMID 24416065), 2013. pubmed.ncbi.nlm.nih.gov
  5. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
  6. Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data (Govaerts et al., Sci Data 2021). Lessertia frutescens (L.) Goldblatt & J.C.Manning (accessed 2026-10-29); WCVP lists Sutherlandia frutescens (L.) W.T.Aiton as a synonym, 2026-10-29. powo.science.kew.org
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.